GS
LKFT

Gilead Sciences’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Gilead Sciences’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$500M Hold
16,707,477
– – 30.34% 2
2026
Q1 		$501M Hold
16,707,477
– – 23.67% 3
2025
Q4 		$551M Hold
16,707,477
– – 28.45% 2
2025
Q3 		$579M Hold
16,707,477
– – 32.31% 1
2025
Q2 		$468M Hold
16,707,477
– – 36.53% 1
2025
Q1 		$419M Hold
16,707,477
– – 35.5% 2
2024
Q4 		$462M Buy
+16,707,477
New +$466M 29.77% 2

Other funds holding LKFT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
DO
denkapparat Operations Berlin, Germany $306M AUM 40.46% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

Gilead Sciences's LKFT Position: Q2 2026 in Review

Gilead Sciences held its Lakefront Biotherapeutics American Depositary Shares (LKFT) position steady in Q2 2026 at 16,707,477 shares worth $500M. The position accounts for 30.34% of the portfolio, ranked #2.

Gilead Sciences first reported a position in LKFT in Q4 2024 and has held it in 7 quarters since. The position peaked at $579M in Q3 2025. 24 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • Gilead Sciences held 16,707,477 shares of Lakefront Biotherapeutics American Depositary Shares worth $500M as of Q2 2026.
  • Gilead Sciences left its Lakefront Biotherapeutics American Depositary Shares share count unchanged in Q2 2026.
  • Lakefront Biotherapeutics American Depositary Shares made up 30.34% of Gilead Sciences's portfolio in Q2 2026, its #2 holding.
  • Gilead Sciences first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2024 and has held it in 7 quarters since.
  • Gilead Sciences's Lakefront Biotherapeutics American Depositary Shares position peaked at $579M in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on Gilead Sciences's 13F filing for Q2 2026, filed 3 Aug 2026.